

OCTOBER
24th-25th
2024



GO NORTE INTERNATIONAL GU DEBATES



 **#GoNorteGUDebates**

Venue:

Parador de Limpias

Fuente del Amor s/n, 39820, Limpias (Cantabria)

Organized by:



GONORTE
Grupo Oncológico



GO NORTE INTERNATIONAL GU DEBATES

Organizing Committee:

Dr. Ignacio Durán

Medical Oncology Department, Hospital Universitario
Marqués de Valdecilla - IDIVAL, Santander

Dr. Nuria Lainez

Medical Oncology Department, Hospital Universitario
de Navarra, Pamplona

Dr. Diego Cacho

Medical Oncology Department, Hospital Universitario
Marqués de Valdecilla - IDIVAL, Santander





THURSDAY, OCTOBER 24th

08:30 REGISTRATION

09:30 - 09:40 OPENING

Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

Dr. Nuria Lainez, Medical Oncology Department, Hospital Universitario de Navarra, Pamplona

09:40 - 11:10 CHALLENGES IN BLADDER CANCER IN 2024: THE NON-MUSCLE INVASIVE DISEASE

Chairs:

Dr. Mario Álvarez-Maestro, Urology Department, Hospital Universitario La Paz, Madrid

Dr. Daniel Castellano, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

09:40 - 09:50 Clinical Vignette

Dr. Carlos Casanova Martín, Urology Department, Hospital Universitario La Paz, Madrid

09:50 - 10:05 Non-muscle-invasive bladder in 2024: State of the art and therapeutic challenges ahead

Dr. Félix Guerrero, Urology Department, Hospital Universitario 12 de Octubre, Madrid

10:05 - 10:20 Intravesical devices in the future management of non-muscle-invasive bladder cancer: Is this the way to go?

Dr. Antoni Vilaseca, Urology Department, Hospital Clínic Barcelona

10:20 - 10:35 The role of systemic therapies in the future management of non-muscle-invasive bladder cancer

Dr. Javier Puente, Medical Oncology Department, Hospital Clínico San Carlos, Madrid

10:35 - 10:50 Non-muscle-invasive bladder cancer: Is the biology of the disease going to be informative to build up the right treatment strategy?

Dr. Marta Dueñas, Researcher, CIEMAT- Fundación de Investigación Hospital 12 de Octubre, Madrid

10:50 - 11:10 Discussion

11:10 - 11:45 COFFEE BREAK ☕

THURSDAY, OCTOBER 24th

11:45 - 12:50 **DIAGNOSING MUSCLE INVASIVE BLADDER CANCER IN 2024: CHALLENGES AND LOOK INTO THE FUTURE**

Chairs:

Dr. Fernando Lozano, Urology Department, Hospital Universitari Vall d'Hebron, Barcelona

Dr. Albert Font, Medical Oncology Department, Hospital Germans Triás i Pujol, Badalona

11:45 - 12:00 **Is Transurethral resection of bladder tumour (TURBT) becoming out of date? The irruption of MRI in the initial staging of muscle-invasive bladder cancer**

VIRTUAL

Dr. Prashant Patel, Urology Department, NHS Foundation Trust, London, United Kingdom

12:00 - 12:15 **Nothing Outperforms Transurethral resection of bladder tumour (TURBT) in the initial staging of muscle-invasive bladder cancer**

Dr. Óscar Rodríguez Faba, Urology Department, Fundació Puigvert, Barcelona

12:15 - 12:30 **MRI is my standard of care in MIBC staging**

Dr. Jerónimo Barrera, Radiology Department, Hospital Clínico San Carlos, Madrid

12:30 - 12:50 **Discussion**

12:50 - 13:35 **MEET WITH THE EXPERT SYMPOSIUM: TRANSFORMING UROTHELIAL CANCER CARE: MULTIDISCIPLINARY APPROACHES**

Chair:

Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

12:50 - 12:55 **Welcome and introductions**

12:55 - 13:15 **Clinical pearls in UC: a new SoC
Interview with experts, Q&A**

Dr. Terence Friedlander, Genitourinary Medical Oncology, University of California San Francisco, USA

Dr. Pablo Maroto, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona



THURSDAY, OCTOBER 24th

13:15 - 13:30 **Management of potential skin toxicities associated with new therapies in Ia/m UC: the importance of a multidisciplinary approach**

Dr. Pablo Maroto, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona

Dr. Elena Carmona, Hospital de la Santa Creu i Sant Pau, Barcelona

13:30 - 13:35 **Summary and close**

Patrocinado por:  **astellas**

13:35 - 15:10 **LUNCH BREAK** ☺

15:10 - 16:20 **MUSCLE INVASIVE BLADDER CANCER: NEW APPROACHES FOR AN OLD DISEASE?**

Chairs:

Dr. Enrique Grande, Medical Oncology Department, MD Anderson Cancer Center Madrid

Dr. Xavier Maldonado, Radiology Department, Vall d'Hebrón Hospital University, Barcelona

15:10 - 15:25 **I am a surgeon, but I will try to preserve your bladder: A critical approach to radical cystectomy in MIBC**

VIRTUAL

Dr. Carme Mir, Urology Department, Hospital Universitario de la Ribera, Alzira

15:25 - 15:40 **I am a surgeon and I believe that nothing outperforms radical cystectomy in MIBC treatment**

Dr. María J. Ribal, Urology Department, Hospital Clinic Barcelona

15:40 - 16:00 **Preserving the bladder in 2024: New paradigms and alternative approaches from a medical oncologist perspective**

Dr. Matt Galsky, Genitourinary Medical Oncology, Mount Sinai Medical Center, New York, USA

16:00 - 16:20 **Discussion**

16:20 - 16:55 **COFFEE BREAK** ☕

THURSDAY, OCTOBER 24th

**16:55-17:40 MEET WITH THE EXPERT SYMPOSIUM
HOW THE EVIDENCE CHANGE THE COURSE IN
PATIENTS WITH LOCALLY ADVANCED AND/OR
METASTATIC UROTHELIAL CARCINOMA?**

Chair:

Dr. Ignacio Durán, Medical Oncology Department, Hospital
Universitario Marqués de Valdecilla - IDIVAL, Santander

Speaker:

Dr. Enrique Grande, Medical Oncology Department, MD
Anderson Cancer Center Madrid

Patrocinado por: **MERCK**

**17:40 - 19:10 ADVANCED BLADDER CANCER SESSION:
THE ENRICHMENT OF THE RICHES?**

Chairs:

Dr. Pablo Maroto, Medical Oncology Department, Hospital de la Santa
Creu i Sant Pau, Barcelona

Dr. Maria José Juan Fita, Medical Oncology Department, Instituto
Valenciano de Oncología, Valencia

**17:40 - 18:00 A new paradigm in 1st line mUC: The role of Enfortumab Vedotin+
Pembrolizumab**

Dr. Terence Friedlander, Genitourinary Medical Oncology, University
of California San Francisco, USA

**18:00 - 18:20 A new paradigm in 1st line mUC: The role of Cisplatin-Gemcitabine
and Nivolumab**

Dr. Matt Galsky, Genitourinary Medical Oncology, Mount Sinai Medical
Center, New York. USA

**18:20 - 18:35 A new paradigm in 1st line mUC: The role of chemotherapy
and maintenance avelumab**

Dr. Alfonso Gómez De Liaño, Medical Oncology Department,
Hospital Insular de Gran Canaria

18:35 - 18:50 The elephant in the room: Who is going to pay for this?

Dr. Carlos Martín Saborido, Advisory member, General Directorate
for the Common Portfolio of SNS and Pharmacy, Ministerio de Sanidad,
Madrid

18:50 - 19:10 Discussion



19:10 - 19:30 2022 GO NORTE GRANTS

19:10 - 19:20 Analysis of the cellular composition of bladder tumor samples for biological study and fibroblast isolation

Dr. Belén Caramelo, Medical Oncology Department, Instituto de Investigación de Valdecilla - IDIVAL, Santander

19:20 - 19:30 The value of patient Education in bladder cancer: VEFOR-1 PROJECT

Dr. Mireia Menéndez, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

19:30 CLOSING OF THE DAY

Dr. Ricardo Fernández, Medical Oncology Department, IMQ Zorrotzaurre y Hospital Universitario de Cruces, Bizkaia

Dr. Diego Cacho, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

20:00 GET TOGETHER DINNER 🍷

Venue: Parador de Limpias



FRIDAY, OCTOBER 25th

08.15 - 08.25 OPENING

Dr. Diego Cacho, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla – IDIVAL, Santander

Dr. Ricardo Fernández, Medical Oncology Department, IMQ Zorrotzaurre y Hospital Universitario de Cruces, Bizkaia

08.25 - 10.10 AGGRESSIVE VARIANT PROSTATE CANCER

Chairs:

Dr. Enrique González-Billalabeitia, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

Dr. Mario Domínguez, Urology Department, Hospital Universitario Marqués de Valdecilla – IDIVAL, Santander

08.25 - 08.35 Case presentation

Dr. Jorge Esteban Villarrubia, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

08.35 - 08.50 CHALLENGES IN THE DIAGNOSIS OF AGGRESSIVE VARIANT PROSTATE CANCER (AVPC): THE PATHOLOGIST'S PERSPECTIVE

VIRTUAL

Dr. Eva Compérat, Department of Pathology, Medical University of Vienna, Austria

08.50 - 09.05 AVPC, MANAGING A CHALLENGING DISEASE: THE MEDICAL ONCOLOGY PERSPECTIVE

Dr. David Lorente, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia

09.05 - 09.25 Discussion

09.25 - 09.35 Case presentation

Dr. Manuel Pérez Martín, Medical Oncology Department, Hospital Clínico San Carlos, Madrid

09.35 - 09.55 Length of therapy in mHSPC patients, how long is not too long?

Dr. David Olmos, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

09.55 - 10.10 Discussion



FRIDAY, OCTOBER 25th

**10:10 - 10:40 CHALLENGES IN PROSTATE CANCER IN 2024:
MANAGING TUMORS WITH DDR GENES DEFECTS**

Chairs:

Dr. Jose Ignacio Rodríguez Gómez, Urology Department, Complejo Hospitalario Universitario de La Coruña

Dr. Miguel Ángel Climent, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia

10:10 - 10:25 PARP inhibitors in combination with NHAs: is EMA the elephant in the room? The clinician perspective

Dr. David Olmos, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

10:25 - 10:40 Discussion

10:40 - 11:15 COFFEE BREAK ☕

**11:15 - 12:35 THINKING OUTSIDE OF THE BOX IN GU CANCER
IN 2024: AN OPPORTUNITY FOR COLLABORATIONS**

Chairs:

Vicens Ruiz De Porras, Researcher, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol-IGTP, Badalona

Dr. Bernardo Herrera, Urology Department, Hospital Universitario Virgen de la Victoria, Málaga

11:15 - 11:30 Exploring resistance in rare cancers : The case of germ cell tumors

Dr. Nerea Muñoz, Medical Oncology Department, Centre Léon Bérard, Lyon

Javier de Nicolás, PhD Student, Centro Nacional de Investigaciones Oncológicas - CNIO, Madrid

11:30 - 11:45 Answering your clinical questions from a different angle in prostate cancer: The basic scientist perspective

Arkaitz Carracedo, Researcher, IKERBASQUE Research Professor & CIC bioGUNE Group Leader, Bilbao

FRIDAY, OCTOBER 25th

11:45 - 12:00 Characterizing urothelial carcinoma across disease settings: The voice of the biologist

Jesús Paramio, Researcher, CIEMAT- Fundación de Investigación
Hospital 12 de Octubre, Madrid

12:00 - 12:15 What do we have to say about bladder cancer? The voice of the patients

Laurent Gemenick, Presidente de CANVES

12:15 - 12:35 Discussion

12:35 - 13:50 RENAL CELL CANCER: THE CALM AFTER THE STORM?

Chairs:

Dr. Urbano Anido, Medical Oncology Department, Complejo Hospitalario
Universitario de Santiago de Compostela

Dr. Teresa Alonso, Medical Oncology Department, Hospital Universitario
Ramón y Cajal, Madrid

HIF PATHWAY IN RENAL CELL CANCER: A SUCCESS OR A DISAPPOINTMENT?

12:35 - 12:50 Is HIF as a valid target for advanced renal cell carcinoma: The biologist's perspective in 2024

VIRTUAL

Dr. Oriol Casanovas, Researcher, Bellvitge Biomedical Research
Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona

12:50 - 13:05 Is HIF as a valid target for advanced renal cell carcinoma: The clinician's perspective in 2024

Dr. Guillermo De Velasco, Medical Oncology Department, Hospital
Universitario 12 de Octubre, Madrid

13:05 - 13:30 KEYNOTE LECTURE

A historical perspective of the Management of RCC in the last decades: From the localized disease to the metastatic setting advances

Dr. Daniel Heng, Medical Oncology Department, Tom Baker Cancer
Center & Baker Cancer Center, Cagliari, Canada

13:30 - 13:50 Discussion





FRIDAY, OCTOBER 25th

13:50 - 14:35 TERAGNOSIS: A NEW PARADIGM IN GU ONCOLOGY

Chairs:

Dr. Daniel Castellano, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

Dr. Mario Domínguez, Urology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

13:50 - 14:05 The role of PET-PSMA in prostate cancer staging: Where are we heading to in 2024?

Dr. Adolfo Gómez, Nuclear Medicine Department, Hospital Universitario 12 de Octubre, Madrid

14:05 - 14:20 Lu-PSMA in advanced prostate cancer in Spain 2024: Are we ready for prime time?

Dr. Marc Simó, Nuclear Medicine Department, Vall d'Hebron Institut de Recerca - VHIR, Barcelona

14:20 - 14:35 Discussion

14:35 CLOSING OF THE SYMPOSIUM

Dr. Ignacio Durán, Medical Oncology, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

Dr. Nuria Lainez, Medical Oncology Department, Hospital Universitario de Navarra, Pamplona



GO NORTE INTERNATIONAL GU DEBATES



SPONSORS

PLATINUM



GOLD



SILVER



BRONZE



AUSPICES



Solicitada la acreditación a la Comisión de Formación Continuada del Sistema Nacional de Salud y de la Consejería de Sanidad de la Comunidad de Madrid.

La asistencia al curso completo es obligatoria para obtener la acreditación. No recibirán los créditos del sistema acreditador ni estudiantes, ni médicos internos residentes, ya que están excluidos del mismo.

TECHNICAL SECRETARIAT:

 **tactics**
20 years working together

 Passatge Batlló 15, 08036 Barcelona

 93 451 17 24

 info@tacticsmd.net

 www.tacticsmd.net